AskBio Named 2021 Life Sciences Awards Company of the Year Winner by Triangle Business Journal
Research Triangle Park, N.C. – May 21, 2021 – Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that it has been honored as one of the Triangle Business Journal’s (TBJ) 2021 Life Sciences Award winners in the Company of the Year category.
The Life Sciences Awards recognize research organizations and individuals that are breaking ground across the life science industry in the Triangle, including in biotechnology, pharmaceuticals, clinical research, human health, medical devices and diagnostics.
“The last 12 months have been truly transformative for AskBio. We continued to advance our best-in-class AAV technology, add to and develop our growing therapeutic pipeline and continued to build on our world-class AAV gene therapy manufacturing platform. Now having joined with Bayer, we are accelerating development of gene therapies for patients who can benefit from them,” said Sheila Mikhail, CEO & Co-Founder, AskBio. “This recognition is a testament to our incredible team at AskBio, who have a relentless commitment to advancing technology and innovation that can have a life-changing impact on patients with genetic diseases.”
TBJ is the leading provider of local business news for the Raleigh-Durham-Chapel Hill area of North Carolina. The Triangle is the fifth fastest-growing life sciences market in the nation. There are currently more than 600 life science companies in North Carolina with a workforce of more than 65,000 people across the state, according to data from the North Carolina Biotechnology Center.
In place of an in-person recognition ceremony due to COVID-19 and gathering restrictions, TBJ featured AskBio and the 2020 Life Sciences Award winners in a special section in their May 21 issue. To read the article, click here.
To learn more about AskBio and our origins in the Triangle life sciences industry, please visit www.askbio.com.
About AskBio
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG acquired in 2020, is a fully integrated AAV gene therapy company dedicated to developing life-saving medicines that have the potential to cure genetic diseases. The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for Pompe disease, Parkinson’s disease and congestive heart failure, as well as out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. AskBio’s gene therapy platform includes Pro10™, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid and promoter library. With global headquarters in Research Triangle Park, North Carolina, and European headquarters in Edinburgh, UK, the company has generated hundreds of proprietary third-generation AAV capsids and promoters, several of which have entered clinical testing. Founded in 2001 and an early innovator in the gene therapy field, the company holds more than 800 patents in areas such as AAV production and chimeric and self-complementary capsids. Learn more at www.askbio.com or follow us on LinkedIn.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.
Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: @BayerPharma
AskBio Forward-Looking Statements
This press release contains “forward-looking statements.” Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include without limitation statements regarding AskBio’s pipeline of development candidates. These forward-looking statements involve risks and uncertainties, many of which are beyond AskBio’s control. Known risks include, among others: AskBio may not be able to execute on its business plans and goals, including meeting its expected or planned regulatory milestones and timelines, its reliance on third-parties, clinical development plans, manufacturing processes and plans, and bringing its product candidates to market, due to a variety of reasons, including the ongoing COVID-19 pandemic, possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved in a timely manner, potential disagreements or other issues with our third-party collaborators and partners, and regulatory, court or agency feedback or decisions, such as feedback and decisions from the United States Food and Drug Administration or the United States Patent and Trademark Office. Any of the foregoing risks could materially and adversely affect AskBio’s business and results of operations. You should not place undue reliance on the forward-looking statements contained in this press release. AskBio does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.
###
Media Contact:
Mark Marmur
+1 973-906-1526
